H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best healthcare stocks with the highest upside. Corcept Therapeutics Incorporated (NASDAQ:CORT) received a rating update from H.C. Wainwright analyst Swayampakula Ramakanth on October 10, who assigned a Buy rating to the stock with a price target of $145.

Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday

The analyst cited the October 1 announcement by specialty pharmacy Curant Rare regarding its selection as a distributor for Korlym by Corcept Therapeutics Incorporated (NASDAQ:CORT). Optime Care, the exclusive pharmacy that has been distributing Korlym since the drug’s launch a decade ago, announced on October 9 the cessation of its distribution of Korlym after the loss of exclusivity.

Ramakanth stated that while these factors delay management’s plans to operate at least two pharmacies by the end of the year, he views these developments as “a fleeting wrinkle” and recommends buying the stock on any weakness.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company that develops and commercializes therapies that adjust the effects of cortisol, a hormone that regulates various bodily functions. The company’s flagship product, Korlym, is FDA-approved for treating Cushing’s syndrome, a disorder caused by excessive cortisol production.

While we acknowledge the potential of CORT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CORT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.